CONZIP (tramadol hydrochloride) by Cipher Pharmaceuticals is extended-release capsules contain tramadol, an opioid agonist, and an inhibitor of reuptake of norepinephrine and serotonin. First approved in 2010.
Drug data last refreshed Just now · AI intelligence enriched 1w ago
CONZIP is an extended-release oral capsule formulation of tramadol hydrochloride, an opioid agonist approved in 2010. It treats moderate to moderately severe pain through dual mechanisms: mu-opioid receptor binding and inhibition of norepinephrine and serotonin reuptake. The active M1 metabolite is up to 6 times more potent than the parent compound in producing analgesia.
Product approaching loss of exclusivity with minimal current Part D claims; brand team likely focused on transition planning rather than growth expansion.
Extended-Release Capsules contain tramadol, an opioid agonist, and an inhibitor of reuptake of norepinephrine and serotonin. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CONZIP at Cipher Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain
Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets
Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar
Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants
A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CONZIP offers limited growth trajectory as the product approaches loss of exclusivity with minimal linked job openings. Roles focus on managed decline, generic transition planning, and cost optimization rather than market expansion or innovation.